Melanoma Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018
Melanoma Disease Pipeline Drugs Assessment
Melanoma is one of the most dangerous cancer of skin. It begins in melanocytes. This cancer is also called as malignant melanoma and cutaneous melanoma. Melanomas can develop anywhere on skin, neck and face are the most common sites. The exact cause of all melanomas isn’t clear, but exposure to ultraviolet (UV) radiation from sunlight or tanning lamps and beds increases your risk of developing melanoma.
Symptoms of melanoma are changes in the existing moles, new patches or spots on skin, dark streak under nails, Band of darker skin around a fingernail or toenail, general symptoms include itching, paining and bleeding. Melanoma is diagnosed by imaging tests and biopsy. Treatment for melanoma includes lymphadenectomy, immunotherapy, targeted therapy, chemotherapy, radiation therapy etc. If the condition gets worsen then excision and surgery is recommended.
By Trial Phase, Melanoma pipeline drugs are segmented as:
- Preclinical Trials
- Phase 1
- Phase 2
- Phase 3
- Phase 4
By Company, Melanoma pipeline drugs are segmented as:
- Daiichi Sankyo Co., Ltd
- Incyte Corporation
- Bristo;-Myers Squibb
- Regeneron Pharmaceuticals
- Takara Bio Inc.
- Immunocore Ltd
- Eisai Inc.
By Drugs, Melanoma pipeline drugs are segmented as:
By Stages of the Condition, Melanoma pipeline drugs are segmented as:
- In situ
- Stage 1
- Stage 2
- Stage 3
- Stage 4
By Route of Administration, Melanoma pipeline drugs are segmented as:
- In June 2016,Incyte Corporation in collaboration with Merck Sharp &Dohme Corp. commenced a phase 3 randomized, double-blind, placebo-controlled study of pembrolizumab (mk-3475) in combination with epacadostat or placebo in subjects with unresectable or metastatic melanoma
- In January 2018, Aprea Therapeutics AB commenced a phase ib/ii study to investigate the safety and clinical activity of apr-246 in combination with dabrafenib in patients with braf v600 mutant unresectable and/or metastatic cutaneous melanoma resistant to dabrafenib/trametinib combination
Melanoma Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Melanoma treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Melanoma disease pipeline drugs development. This report studies the dynamics of the Melanoma Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Melanoma disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
Key Features of the Report:
- Provides the information related to universities and research institutes working in the therapeutics development
- Report comprehensively covers the all active and discontinued studies
- Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
- Presents the prominent targets for drug development in each stage of clinical trial
- Provides the in-depth analysis on the each drug candidates in the clinical trial phases